Trial Profile
A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 01 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 01 Dec 2015 Planned primary completion date changed from 1 Oct 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.